We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Test for C Difficile Toxins

By HospiMedica staff writers
Posted on 17 Oct 2005
A new test directly detects Clostridium difficile toxins A and B from fecal samples in only 20 minutes.

Until recently, all toxigenic strains of C difficile were thought to produce both toxins A and B, and toxin A was thought to play the most significant role in disease progression. More...
New reports now document the existence of A-/B+ strains of C difficile linked to C difficile-associated disease (CDAD). The ability to detect both toxins quickly is now extremely important, as reports from around the world increasingly report CDAD caused by strains that are negative for toxin A but positive for toxin B.

The new test, from Oxoid (Basingstoke, UK), is called Xpect Clostridium difficile toxin A/B test and it detects both toxins A and B. This minimizes false-negatives caused by A-/B+ strains. The test is simple, with no specimen processing required and minimal manual intervention. Diluted sample is mixed with conjugate and added to the test cassette. Within 20 minutes, the result is clearly visible. Such speed results in early therapy and prompt initiation of infection-control procedures.

Toxigenic C difficile strains are a frequent cause of infectious nosocomial diarrhea associated with recent antibiotic therapy. Those most at risk include the elderly, patients with underlying illnesses, and immunosuppressed patients. Complications include pseudomembranous colitis (PMC), toxic megacolon, perforations of the colon, sepsis, and even death. C difficile infection in a hospital increases morbidity and mortality among patients, increases therapeutic interventions and infection-control procedures, and increases length of stay for affected patients.




Related Links:
Oxoid

Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Digital Radiography System (Ceiling Free)
Digix CF Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.